Published in Nature Metabolism, the review highlighted how incretin-based drugs, originally for diabetes and obesity, may also treat brain diseases like Alzheimer's and Parkinson's. These drugs reduce inflammation and improve brain energy use. Early results were promising, with larger human trials now underway.